BioGaia signs agreement with pharmaceutical company in Indonesia
(Thomson Reuters ONE) -
The agreement with the Indonesian pharmaceutical company Interbat refers to
sales of BioGaia Probiotic drops in Indonesia under the BioGaia brand. Launch is
estimated during the first quarter of 2011.
- We are very much looking forward to the cooperation with Interbat. The company
has a strong local position and regularly visits paediatricians, who are the
target group for our probiotic drops, says Peter Rothschild, President, BioGaia
AB.
Interbat is the seventh largest pharmaceutical company in Indonesia with 1 500
employees. Most of their business is manufacturing and sales of their own
prescription and over the counter pharmaceuticals. The representatives from
Interbat regularly visit some 30 000 medical doctors in Indonesia and Interbat
is represented in 1 200 of Indonesian hospitals. Of the 900 Interbat
representatives around 700 will sell the BioGaia Probiotic drops.
Indonesia has 230 million inhabitants and the knowledge of probiotics is fairly
high among the general public. The potential for the market is therefore
estimated as large despite the relatively low level of income in the country.
BioGaia Probiotic tablets are already on the market in Indonesia through the
pharmaceutical company Kalbe Farma.
[HUG#1396096]
Press release March 22 2010 (pdf): http://hugin.info/86913/R/1396096/352593.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2010 - 08:57 Uhr
Sprache: Deutsch
News-ID 1011712
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Stockholm
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 67 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioGaia signs agreement with pharmaceutical company in Indonesia
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioGaia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
